Evaluating Immune Function Tests in People With HIV
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00067795 |
Recruitment Status
:
Completed
First Posted
: August 28, 2003
Last Update Posted
: November 22, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV Infections |
The efficiency of the immune response to HIV antigens is the critical feature that allows some individuals with chronic HIV infection to maintain low level viremia (less than 3000 copies/ml). The fundamental measurement of this response is the steady state level of viremia in the absence of antiretroviral drugs. However, using this clinical endpoint in vaccine and drug trials is time-consuming. Several laboratory assays of HIV T cell function have been developed to measure the key characteristics of an efficient immune response. This study will evaluate these assays in two distinct patient populations.
Two patient cohorts will be followed in this study. Cohort A will enroll patients who are stable on highly active antiretroviral therapy (HAART). These patients will have been on the same HAART regimen for at least 9 months prior to study entry. Cohort B will enroll patients with chronic HIV infection and efficient immune control. These patients will have not been on any antiretroviral drugs for at least 6 months and will have viral loads less than 3,000 copies/ml. Participants in both cohorts will have blood drawn at study entry and Weeks 12 and 24. Blood samples will be used for CD4/CD8 cell count, plasma HIV-1 RNA, and immunologic assays.
Study Type : | Observational |
Enrollment : | 54 participants |
Time Perspective: | Prospective |
Official Title: | HIV Antigen-Specific Immune Responses - A Comparison of Alternative In Vitro Assays From Subjects Characterized as Either "Stable HAART" or "Efficient Immune Control" |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for Cohorts A and B:
- HIV-1 infection
- CD4 cell count > 300 cells/mm3 within 60 days prior to study entry
- Negative pregnancy test within 14 days of starting study
- Agree to use acceptable methods of contraception while in study
Inclusion Criteria for Cohort A (Stable HAART) Only:
- Stable HAART regimen, defined as the suppression of viral load to undetectable levels, for at least 9 months prior to study entry
- Viral load < 75 copies/ml on at least three occasions within 9 months prior to study entry, with at least one of these values obtained between 6 and 9 months prior to study entry
- No single viral load >= 75 copies/ml within 9 months prior to study entry
Inclusion Criteria for Cohort B (Efficient Immune Control) Only:
- Not taking any antiretroviral drugs for at least 6 months prior to study entry
- Meets study definition of efficient immune control (generally HIV-1 viral load < 3,000 copies/ml, with some exceptions)
Exclusion Criteria:
- Pregnancy or breast-feeding
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
- History of an AIDS-defining opportunistic infection

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00067795
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35924-2050 | |
United States, California | |
UC Davis Medical Center | |
Sacremento, California, United States, 95814 | |
United States, Florida | |
University of Miami | |
Miami, Florida, United States, 33136-1013 | |
United States, Illinois | |
Rush-Presbyterian/St. Lukes | |
Chicago, Illinois, United States, 60612-3806 | |
United States, Ohio | |
Case Western Reserve University | |
Cleveland, Ohio, United States, 44106-5083 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213-2582 |
Study Chair: | R. Pat Bucy, MD, PhD | University of Alabama at Birmingham |
Publications of Results:
Other Publications:
ClinicalTrials.gov Identifier: | NCT00067795 History of Changes |
Other Study ID Numbers: |
ACTG A5181 |
First Posted: | August 28, 2003 Key Record Dates |
Last Update Posted: | November 22, 2010 |
Last Verified: | November 2010 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Treatment Experienced Antiretroviral Therapy, Highly Active HIV Antigens |
Cohort Studies Immunity, Cellular T-Lymphocytes |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |